

-216-

63. The method of Claim 44 wherein the antineoplastic agent is etoposide.

64. The method of Claim 44 wherein the antineoplastic agent is fluorouracil (5-FU).

5 65. The method of Claim 44 wherein the antineoplastic agent is fluoxymestrone.

66. The method of Claim 44 wherein the antineoplastic agent is gemcitabine.

10 67. The method of Claim 44 wherein the antineoplastic agent is goserelin.

68. The method of Claim 44 wherein the antineoplastic agent is irinotecan.

69. The method of Claim 44 wherein the antineoplastic agent is ketoconazole.

15 70. The method of Claim 44 wherein the antineoplastic agent is letrozol.

71. The method of Claim 44 wherein the antineoplastic agent is leucovorin.

20 72. The method of Claim 44 wherein the antineoplastic agent is levamisole.

73. The method of Claim 44 wherein the antineoplastic agent is megestrol.

74. The method of Claim 44 wherein the antineoplastic agent is mitoxantrone.

25 75. The method of Claim 44 wherein the antineoplastic agent is paclitaxel.

76. The method of Claim 44 wherein the antineoplastic agent is raloxifene.

30 77. The method of Claim 44 wherein the antineoplastic agent is retinoic acid.

-217-

78. The method of Claim 44 wherein the antineoplastic agent is tamoxifen.

79. The method of Claim 44 wherein the antineoplastic agent is thiotepa.

5 80. The method of Claim 44 wherein the antineoplastic agent is topotecan.

81. The method of Claim 44 wherein the antineoplastic agent is toremifene.

10 82. The method of Claim 44 wherein the antineoplastic agent is vinorelbine.

83. The method of Claim 44 wherein the antineoplastic agent is vinblastine.

84. The method of Claim 44 wherein the antineoplastic agent is vincristine.

15 85. The method of Claim 44 wherein the antineoplastic agent is selenium (selenomethionine).

86. The method of Claim 44 wherein the antineoplastic agent is ursodeoxycholic acid.

16 87. The method of Claim 44 wherein the antineoplastic agent is sulindac sulfone.

88. The method of Claim 44 wherein the antineoplastic agent is eflornithine (DFMO).

17 89. The method of Claim 44 wherein the neoplasia is selected from the group consisting of lung cancer,
breast cancer, gastrointestinal cancer, bladder cancer,
head and neck cancer and cervical cancer.


18 90. A combination comprising a
cyclooxygenase-2 inhibitor and one or more
antineoplastic agents, wherein said antineoplastic
agents are selected from the group consisting of
anastrozole, calcium carbonate, capecitabine,

-218-

carboplatin, cisplatin, Cell Pathways CP-461,
docetaxel, doxorubicin, etoposide fluoxymestrine,
gemcitabine, goserelin, irinotecan, ketoconazole,
letrozol, leucovorin, levamisole, megestrol,
5 mitoxantrone, paclitaxel, raloxifene, retinoic
acid, tamoxifen, thiotepa, topotecan, toremifene,
vinorelbine, vinblastine, vincristine, selenium
(selenomethionine), sulindac sulfone, exemestane
and eflornithine (DFMO).

10 91. The combination of Claim 90 wherein the
cyclooxygenase-2 inhibitor is selected from compounds,
and their pharmaceutically acceptable salts thereof, of
the group consisting of:

1)



15 JTE-522, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-
2-fluorobenzenesulfonamide,

2)

20 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-
(methyl-5-pyridinyl)pyridine,

3)

2-(3,5-difluorophenyl)-3-4-
(methylsulfonyl)phenyl)-2-cyclopenten-1-one,

4)